cytarabine has been researched along with glasdegib in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 17 (70.83) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, G; Cortes, JE; DesJardins, P; Fiedler, W; Heidel, FH; Hellmann, A; Heuser, M; Laird, AD; Ma, WW; Montesinos, P; O'Connell, A; Ottmann, O; Pollyea, DA; Robak, T; Shaik, MN; Smith, BD; Zeremski, M | 1 |
| Hoy, SM | 1 |
| By, K; Del Valle, PL; Farrell, AT; Goldberg, KB; Leong, R; Liu, C; Norsworthy, KJ; Pazdur, R; Przepiorka, D; Shen, YL; Sheth, CM; Subramaniam, S; Zhuang, L | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| Fathi, AT | 1 |
| Robak, T; Wolska-Washer, A | 1 |
| Goldsmith, SR; Lovell, AR; Schroeder, MA | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Burnett, A; Stone, R | 1 |
| Candoni, A; Chan, G; Cortes, JE; Ferdinand, R; Fiedler, W; Heidel, FH; Heuser, M; Leber, B; Ma, WW; Montesinos, P; O'Brien, T; O'Connell, A; Pollyea, DA; Robak, T; Sekeres, MA; Smith, BD | 1 |
| Bell, TJ; Bhattacharyya, H; Cappelleri, JC; Cortes, JE; Hoang, CJ; Johnson, C; Kwon, Y; Solem, CT | 1 |
| Chan, G; Cortes, JE; Lin, S; Ruiz-Garcia, A; Shaik, N | 1 |
| Candoni, A; Clark, RE; Cortes, JE; Heuser, M; Leber, B; Montesinos, P; Vyas, P; Zeidan, AM | 1 |
| Chacim, S; Mariz, JM; Tavares, M | 1 |
| Daver, N; DiNardo, CD; Fathi, AT; Pollyea, DA; Vyas, P; Wei, AH | 1 |
| Galinsky, I; Hoang, CJ; McBride, A; Newman, MJ; Paul, S; Relias, V; Ryan, JC; Saneeymehri, S; Stanislaus, G; Tobin, J | 1 |
| Feld, J; Navada, SC; Silverman, LR | 1 |
| Heaney, ML; Sarkaria, SM | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Burzdikaite, P; Dapkeviciute, A; Daukelaite, G; Davainis, L; Griskevicius, L; Maneikis, K; Pugaciute, B; Ringeleviciute, U; Staras, V; Zucenka, A | 1 |
| Bell, T; Brown, A; Cappelleri, JC; Chan, G; Daniele, P; Tremblay, G | 1 |
| Chan, G; Cortes, JE; Fiedler, W; Heuser, M; Hoang, CJ; Leber, B; Ma, WW; Merchant, A; Montesinos, P; O'Brien, T; O'Connell, A; Papayannidis, C; Pérez-Simón, JA; Sekeres, MA; Smith, BD; Zeremski, M | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
10 review(s) available for cytarabine and glasdegib
| Article | Year |
|---|---|
Glasdegib: First Global Approval.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Approval; Europe; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Signal Transduction; United States | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
AML: New Drugs but New Challenges.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines | 2020 |
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2020 |
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Quinuclidines; Sulfonamides | 2020 |
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Cell Line, Tumor; Clinical Trials as Topic; Cytarabine; Drug Approval; Drug Evaluation, Preclinical; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Signal Transduction; Smoothened Receptor; United States | 2021 |
Glasdegib in newly diagnosed acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2021 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
8 trial(s) available for cytarabine and glasdegib
| Article | Year |
|---|---|
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Phenylurea Compounds; Prognosis; Survival Rate | 2019 |
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Comorbidity; Cytarabine; Dose-Response Relationship, Drug; Drug Approval; Drug Labeling; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Smoothened Receptor; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2019 |
Glasdegib in the treatment of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Phenylurea Compounds; Prognosis; Survival Rate | 2019 |
A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherap
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Phenylurea Compounds; Survival Analysis | 2020 |
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Time Factors; Treatment Outcome; United States | 2020 |
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Interactions; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Pharmacists; Phenylurea Compounds; Physicians | 2021 |
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Phenylurea Compounds; Survival Analysis; Treatment Outcome | 2021 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
6 other study(ies) available for cytarabine and glasdegib
| Article | Year |
|---|---|
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds | 2019 |
Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Cytarabine; Drug Approval; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2019 |
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Blood Transfusion; Cause of Death; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Multicenter Studies as Topic; Phenylurea Compounds; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2020 |
Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Compassionate Use Trials; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Retrospective Studies; Treatment Outcome | 2021 |
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Sulfonamides | 2021 |